Patent Grant
8034941
The present invention relates to new substituted imidazopyridazinones and imidazopyridones of general formula
the tautomers, the enantiomers, the diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV), the preparation thereof, the use thereof for the prevention or treatment of diseases or conditions associated with an increased DPP-IV activity or capable of being prevented or alleviated by reducing the DPP-IV activity, particularly type I or type II diabetes mellitus, the pharmaceutical compositions containing a compound of general formula (I) or a physiologically acceptable salt thereof as well as processes for the preparation thereof.
The present invention thus relates to the above compounds of general formula I which have valuable pharmacological properties, the pharmaceutical compositions containing the pharmacologically effective compounds, the use thereof and processes for the preparation thereof.
In the above general formula I
R1 denotes a C1-3-alkyl group substituted by a group Ra, where
Compounds of the above general formula I which contain one or more groups that can be cleaved in vivo are so-called prodrugs.
The carboxy groups mentioned in the definition of the above mentioned groups may be replaced by a group which can be converted into a carboxy group in vivo or by a group which is negatively charged under physiological conditions,
and furthermore the amino and imino groups mentioned in the definition of the above mentioned groups may be substituted by a group which can be cleaved in vivo. Such groups are described for example in WO 98/46576 and by N. M. Nielsen et al. in International Journal of Pharmaceutics 39, 75-85 (1987).
By a group which can be converted in vivo into a carboxy group is meant, for example, a hydroxymethyl group, a carboxy group esterified with an alcohol wherein the alcohol moiety is preferably a C1-6-alkanol, a phenyl-C1-3-alkanol, a C3-9-cycloalkanol, while a C5-8-cycloalkanol may additionally be substituted by one or two C1-3-alkyl groups, a C5-8-cycloalkanol wherein a methylene group in the 3 or 4 position is replaced by an oxygen atom or by an imino group optionally substituted by a C1-3-alkyl, phenyl-C1-3-alkyl, phenyl-C1-3-alkyloxycarbonyl or C2-6-alkanoyl group and the cycloalkanol moiety may additionally be substituted by one or two C1-3-alkyl groups, a C4-7-cycloalkenol, a C3-5-alkenol, a phenyl-C3-5-alkenol, a C3-5-alkynol or phenyl-C3-5-alkynol with the proviso that no bonds to the oxygen atom start from a carbon atom which carries a double or triple bond, a C3-8-cycloalkyl-C1-3-alkanol, a bicycloalkanol with a total of 8 to 10 carbon atoms which may additionally be substituted in the bicycloalkyl moiety by one or two C1-3-alkyl groups, a 1,3-dihydro-3-oxo-1-isobenzofuranol or an alcohol of formula
Rp—CO—O—(RqCRr)—OH,
wherein
Moreover, the saturated alkyl and alkyloxy moieties which contain more than 2 carbon atoms mentioned in the foregoing definitions and those that follow, unless otherwise stated, also include the branched isomers thereof such as, for example, the isopropyl, tert.butyl, isobutyl group, etc.
Preferred compounds of the above general formula I are those wherein
R1 denotes a methyl group substituted by a group Ra, where
Particularly preferred are those compounds of the above general formula I wherein
R1 denotes a methyl group substituted by a group Ra, where
Most particularly preferred are those compounds of the above general formula I wherein
R1 denotes a 4-oxo-3,4-dihydro-quinazolin-2-ylmethyl group,
a dibenzo[b,f][1,4]oxazepin-11-ylmethyl group,
a phenanthridin-6-ylmethyl group,
a phenanthren-9-ylmethyl group or
a naphtho[1,2-d]oxazol-2-ylmethyl or naphtho[2,1-d]oxazol-2-ylmethyl group,
R2 denotes a hydrogen atom or a methyl group,
Y denotes a nitrogen atom,
R3 denotes a 2-butyn-1-yl group
and
R4 denotes a (3-amino-piperidin-1-yl) group,
the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
The following compounds of general formula I deserve special mention:
the enantiomers, the mixtures thereof and the salts thereof.
According to the invention the compounds of general formula I are obtained by methods known per se, for example by the following methods:
a) deprotecting a compound of general formula
wherein R1, R2, Y and R3 are as hereinbefore defined and
R4″ denotes one of the groups mentioned for R4 hereinbefore which contain an imino, amino or alkylamino group, while the imino, amino or alkylamino group is substituted by a protective group.
The liberating of an amino group from a protected precursor is a standard reaction in synthetic organic chemistry. There are many examples of suitable protective groups. A summary of the chemistry of protective groups can be found in Theodora W. Greene and Peter G. M. Wuts, Protective Groups in Organic Synthesis, Second Edition, 1991, published by John Wiley and Sons, and in Philip J. Kocienski, Protecting Groups, published by Georg Thieme, 1994.
The following are examples of protective groups:
the tert.-butyloxycarbonyl group which can be cleaved by treating with an acid such as for example trifluoroacetic acid or hydrochloric acid or by treating with bromotrimethylsilane or iodotrimethylsilane, optionally using a solvent such as methylene chloride, ethyl acetate, dioxane, methanol, isopropanol or diethylether at temperatures between 0° C. and 80° C.,
the 2,2,2-trichloroethoxycarbonyl group which can be cleaved by treating with metals such as for example zinc or cadmium in a solvent such as acetic acid or a mixture of tetrahydrofuran and a weak aqueous acid at temperatures between 0° C. and the boiling temperature of the solvent used and
the carbobenzyloxycarbonyl group which can be cleaved for example by hydrogenolysis in the presence of a noble metal catalyst such as for example palladium-charcoal and a solvent such as for example alcohols, ethyl acetate, dioxane, tetrahydrofuran or mixtures of these solvents at temperatures between 0° C. and the boiling point of the solvent, by treating with boron tribromide in methylene chloride at temperatures between −20° C. and ambient temperature, or by treating with aluminium chloride/anisol at temperatures between 0° C. and ambient temperature.
Moreover, the compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers, as mentioned hereinbefore. Thus, for example, cis/trans mixtures may be resolved into their cis and trans isomers, and compounds with at least one stereocentre may be separated into their enantiomers.
Thus, for example, the cis/trans mixtures obtained may be resolved by chromatography into the cis and trans isomers thereof, the compounds of general formula I obtained which occur as racemates may be separated by methods known per se (cf. Allinger N. L. and Eliel E. L. in “Topics in Stereochemistry”, Vol. 6, Wiley Interscience, 1971) into their optical antipodes and compounds of general formula I with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known per se, e.g. by chromatography and/or fractional crystallisation, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above.
The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids in common use are e.g. the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-O-p-toluoyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid or quinic acid. An optically active alcohol may be for example (+)- or (−)-menthol and an optically active acyl group in amides, for example, may be a (+)- or (−)-menthyloxycarbonyl.
Furthermore, the compounds of formula I obtained may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids. Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, methanesulphonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.
Moreover, if the new compounds of formula I thus obtained contain a carboxy group, they may subsequently, if desired, be converted into the salts thereof with inorganic or organic bases, particularly for pharmaceutical use into the physiologically acceptable salts thereof. Suitable bases for this purpose include for example sodium hydroxide, potassium hydroxide, arginine, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.
The compounds of general formula II used as starting materials are either known from the literature or may be obtained by methods known from the literature (cf. Examples I to XVI).
As already mentioned hereinbefore, the compounds of general formula I according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibiting effect on the enzyme DPP-IV.
The biological properties of the new compounds were investigated as follows:
The ability of the substances and their corresponding salts to inhibit the DPP-IV activity can be demonstrated in a test set-up in which an extract of human colon carcinoma cell line Caco-2 is used as the DPP IV source. The differentiation of the cells in order to induce the DPP-IV expression was carried out as described by Reiher et al. in an article entitled “Increased expression of intestinal cell line Caco-2”, which appeared in Proc. Natl. Acad. Sci. Vol. 90, pages 5757-5761 (1993). The cell extract was obtained from cells solubilised in a buffer (10 mM Tris HCl, 0.15 M NaCl, 0.04 t.i.u. aprotinin, 0.5% Nonidet-P40, pH 8.0) by centrifuging at 35,000 g for 30 minutes at 4° C. (to remove cell debris).
The DPP-IV assay was carried out as follows:
50 μl substrate solution (AFC; AFC is amido-4-trifluoromethylcoumarin), final concentration 100 μM, were placed in black microtitre plates. 20 μl of assay buffer (final concentrations 50 mM Tris HCl pH 7.8, 50 mM NaCl, 1% DMSO) was pipetted in. The reaction was started by adding 30 μl of solubilised Caco-2 protein (final concentration 0.14 μg of protein per well). The test substances to be investigated were typically added prediluted in 20 μl, and the volume of assay buffer was then reduced accordingly. The reaction was carried out at ambient temperature, incubating for 60 minutes. Then the fluorescence was measured in a Victor 1420 Multilabel Counter, the excitation wavelength being 405 nm and the emission wavelength being 535 nm. Blank readings (corresponding to 0% activity) were obtained in mixtures without any Caco-2 protein (volume replaced by assay buffer), control values (corresponding to 100% activity) were obtained in mixtures with no substance added. The potency of the test substances in question, expressed as IC50 values, was calculated from dosage/activity curves consisting of 11 measuring points in each case. The following results were obtained:
The compounds prepared according to the invention are well tolerated, as for example when 10 mg/kg of the compound of Example 1 were administered to rats by oral route no changes in the animals' behaviour could be detected.
In view of their ability to inhibit DPP-IV activity, the compounds of general formula I according to the invention and the corresponding pharmaceutically acceptable salts thereof are suitable for treating all those conditions or illnesses which can be influenced by the inhibition of the DPP-IV activity. It is therefore to be expected that the compounds according to the invention will be suitable for the prevention or treatment of diseases or conditions such as type I and type II diabetes mellitus, diabetic complications, metabolic acidosis or ketosis, insulin resistance, dyslipidaemias of various origins, arthritis, atherosclerosis and related diseases, obesity, allograft transplantation and calcitonin-induced osteoporosis. In addition these substances are capable of preventing B-cell degeneration such as e.g. apoptosis or necrosis of pancreatic B-cells. The substances are also suitable for improving or restoring the function of pancreatic cells and also increasing the number and size of pancreatic B-cells. Additionally, and on the basis of the role of the Glucagon-Like Peptides, such as e.g. GLP-1 and GLP-2 and their link with DPP-IV inhibition, it is likely that the compounds according to the invention are suitable for achieving, inter alia, a sedative or anxiety-relieving effect and also of favourably affecting catabolic states after operations or hormonal stress responses or of reducing mortality or morbidity after myocardial infarct. They are also suitable for treating all conditions which are connected with the above mentioned effects and which are mediated by GLP-1 or GLP-2. The compounds according to the invention may also be used as diuretics or antihypertensives and are suitable for preventing and treating acute renal failure. They are also suitable for the prevention and treatment of chronic inflammatory intestinal diseases. It is also expected that DPP-IV inhibitors and hence also the compounds according to the invention may be used to treat infertility or to improve fertility in humans or mammals, particularly when the infertility is connected with insulin resistance or polycystic ovary syndrome. The substances are also suitable for treating deficiencies of growth hormone which are associated with reduced stature.
The compounds according to the invention may also be used in conjunction with other active substances. Therapeutic agents which are suitable for such combinations include, for example, antidiabetics, such as metformin, sulphonylureas (e.g. glibenclamide, tolbutamide, glimepiride), nateglinide, repaglinide, thiazolidinedione (e.g. rosiglitazone, pioglitazone), PPAR-gamma agonists (e.g. GI 262570), alpha-glucosidase inhibitors (e.g. acarbose, voglibose), alpha2 antagonists, insulin and insulin analogues, GLP-1 and GLP-1 analogues (e.g. exendin-4) or amylin. Also, inhibitors of protein tyrosine phosphatase 1, substances which influence deregulated glucose production in the liver, such as e.g. inhibitors of glucose-6-phosphatase, or fructose-1,6-bisphosphatase, glycogen phosphorylase, glucagon receptor antagonists and inhibitors of phosphoenol pyruvate carboxykinase, glycogen synthase kinase or pyruvate dehydrokinase, lipid lowering agents, such as HMG-CoA-reductase inhibitors (e.g. simvastatin, atorvastatin), fibrates (e.g. bezafibrate, fenofibrate), nicotinic acid and its derivatives, cholesterol absorption inhibitors such as for example ezetimibe, bile acid-binding substances such as for example cholestyramine, HDL-raising compounds such as for example inhibitors of CETP or regulators of ABC1 or active substances for the treatment of obesity, such as e.g. sibutramine or tetrahydrolipostatin, or β3-agonists such as SB-418790 or AD-9677.
It is also possible to combine the compounds with drugs for treating high blood pressure such as e.g. AII antagonists or ACE inhibitors, diuretics, β-blockers, etc., or combinations thereof.
The dosage required to achieve such an effect is expediently, by intravenous route, 1 to 100 mg, preferably 1 to 30 mg, and by oral route 1 to 1000 mg, preferably 1 to 100 mg, in each case 1 to 4 times a day. For this purpose, the compounds of formula I prepared according to the invention, optionally combined with other active substances, may be incorporated together with one or more inert conventional carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof into conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories.
The Examples that follow are intended to illustrate the invention:
Preparation of the starting compounds:
317 mg 11-chloromethyl-dibenzo[b,f][1,4]oxazepin are added to 400 mg 2-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one and 276 mg potassium carbonate in 4 ml N,N-dimethylformamide. The reaction mixture is stirred for two hours at 80° C. For working up it is combined with water and the precipitate formed is suction filtered. The crude product is purified by chromatography over a silica gel column with methylene chloride/methanol (100:0 to 70:30) as eluant.
Yield: 120 mg (20% of theory)
Mass spectrum (ESI+): m/z=594 [M+H]+
The following compounds are obtained analogously to Example I:
Rf value: 0.41 (silica gel, cyclohexane/ethyl acetate=3:7)
Mass spectrum (ESI+): m/z=592 [M+H]+
Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate=2:8)
Mass spectrum (ESI+): m/z=608 [M+H]+
Mass spectrum (ESI+): m/z=474, 476 [M+H]+
Rf value: 0.80 (silica gel, methylene chloride/ethanol=9:1)
Rf value: 0.50 (silica gel, methylene chloride/methanol=19:1)
Rf value: 0.40 (silica gel, petroleum ether/ethyl acetate=1:4)
Mass spectrum (ESI+): m/z=426 [M+H]+
2.50 g 3-(tert.-butyloxycarbonylamino)-piperidine are added to 2.65 g 2-bromo-3-(2-butyn-1-yl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one and 2.12 g sodium carbonate in 5 ml dimethylsulphoxide. The reaction mixture is stirred overnight at 85° C.
After cooling to ambient temperature it is combined with water and extracted with ethyl acetate. The combined organic phases are dried over magnesium carbonate and evaporated down. The crude product is further reacted without any further purification.
Mass spectrum (ESI+): m/z=387 [M+H]+
The following compounds are obtained analogously to Example II:
Rf value: 0.15 (silica gel, cyclohexane/ethyl acetate=3:7)
Mass spectrum (ESI+): m/z=401 [M+H]+
Mass spectrum (ESI+): m/z=594 [M+H]+
Mass spectrum (ESI+): m/z=594 [M+H]+
Rf value: 0.70 (silica gel, methylene chloride/ethanol=9:1)
Rf value: 0.65 (silica gel, methylene chloride/methanol=9:1)
Mass spectrum (ESI+): m/z=568 [M+H]+
Mass spectrum (ESI+): m/z=387 [M+H]+
Rf value: 0.50 (silica gel, methylene chloride/ethanol=9:1)
0.63 ml hydrazine hydrate are added dropwise to 3.68 g methyl 2-bromo-3-(2-butyn-1-yl)-5-formyl-3H-imidazole-4-carboxylate in 50 ml of ethanol. The reaction mixture is stirred for one hour at ambient temperature, then 3 ml acetic acid are added and the reaction mixture is refluxed for a further hour. The precipitate formed is suction filtered, washed with ethanol and diethyl ether and dried.
Yield: 2.65 g (77% of theory)
Mass spectrum (ESI+): m/z=267, 269 [M+H]+
45 ml diisobutylaluminum hydride solution (1M in toluene) are added dropwise to 12.45 g dimethyl 2-bromo-3-(2-butyn-1-yl)-1H-imidazole-4,5-dicarboxylate in 150 ml of tetrahydrofuran under an argon atmosphere at −65° C. The reaction mixture is stirred for two hours at −65° C., then another 9 ml diisobutylaluminum hydride solution are added. After another hour the reaction mixture is quenched at −65° C. with a mixture of 1 M hydrochloric acid and tetrahydrofuran (1:1) and stirred for ten minutes. Then the cooling bath is removed, the reaction mixture is diluted with water and extracted with ethyl acetate. The combined organic phases are dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography over a silica gel column with cyclohexane/ethyl acetate (2:1 to 1:1).
Yield: 9.58 g (85% of theory)
Mass spectrum (ESI+): m/z=285, 287 [M+H]+
The following compounds are obtained analogously to Example IV:
Mass spectrum (ESI+): m/z=301, 303 [M+H]+
4.53 ml of 1-bromo-2-butyne are added to 13.20 g dimethyl 2-bromo-1H-imidazole-4,5-dicarboxylate and 8.57 g potassium carbonate in 70 ml N,N-dimethylformamide and the reaction mixture is stirred overnight at ambient temperature.
For working up it is combined with water and extracted with ethyl acetate. The combined organic phases are dried over magnesium sulphate and evaporated down.
Yield: 14.58 g (92% of theory)
Mass spectrum (ESI+): m/z=315, 317 [M+H]+
The following compounds are obtained analogously to Example V:
Mass spectrum (ESI+): m/z=331, 333 [M+H]+
6.11 ml bromine are added to 19.80 g dimethyl 1H-imidazole-4,5-dicarboxylate and 14.92 g potassium carbonate in 600 ml methylene chloride. The reaction mixture is stirred for one hour at ambient temperature, then a mixture of saturated sodium sulphite solution and saturated sodium chloride solution (1:1) is added. The organic phase is largely separated off and the aqueous phase is extracted with ethyl acetate several times. The combined organic phases are dried over magnesium sulphate and evaporated down, leaving about 7.40 g crude product. The aqueous phase is combined with ethyl acetate and extracted overnight in an extraction apparatus. The ethyl acetate extract is evaporated down and the flask residue is combined with the crude product already obtained.
Yield: 13.10 g (46% of theory)
Mass spectrum (ESI+): m/z=263, 265 [M+H]+
0.50 ml of 1-bromo-2-butyne are added to 1.30 g 2-bromo-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one and 0.99 ml Hünig base in 30 ml of N,N-dimethylformamide. The reaction mixture is stirred for three hours at ambient temperature. Then the solvent is distilled off in vacuo using the rotary evaporator. The flask residue is stirred with 40 ml of water and 0.5 ml concentrated aqueous ammonia solution, suction filtered and washed with ethanol as well as diethyl ether.
Yield: 1.30 g (82% of theory)
Rf value: 0.60 (silica gel, cyclohexane/ethyl acetate=3:7)
Mass spectrum (ESI+): m/z=281, 283 [M+H]+
5.20 ml of a 1.8 M solution of bromine in acetonitrile are slowly added dropwise to 1.40 g of 7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one and 1.30 g potassium carbonate in 40 ml acetonitrile. Then the reaction mixture is heated to 70° C., whereupon the mixture is rapidly decolourised. More bromine solution and potassium carbonate are added batchwise until the reaction has ended, according to HPLC-MS. For working up the reaction mixture is evaporated down, stirred with 100 ml of water and suction filtered. The filtrate is acidified with 1 M hydrochloric acid and extracted with ethyl acetate. The combined extracts are dried over sodium sulphate and evaporated down.
Yield: 1.30 g (61% of theory)
Rf value: 0.37 (silica gel, methylene chloride/methanol=9:1)
Mass spectrum (ESI+): m/z=229, 231 [M+H]+
A solution of 4.00 g sodium nitrite in 15 ml of water is added dropwise at 50° C. to 2.20 g of 4-amino-7-methyl-3H-imidazo[4,5-d]pyridazine in a mixture of 30 ml acetic acid, 5 ml of water and 0.5 ml concentrated sulphuric acid. The reaction mixture is stirred for a further two hours at 50° C. and then heated to 90° C. for one hour. After cooling to ambient temperature the reaction mixture is diluted with 30 ml of water. The precipitate formed is suction filtered, washed with water, ethanol and diethyl ether and dried.
Yield: 1.00 g (45% of theory)
Mass spectrum (ESI+): m/z=151 [M+H]+
A mixture of 2.00 g 5-acetyl-3H-imidazole-4-carbonitrile and 4.00 ml hydrazine hydrate in 50 ml of ethanol is heated to 100° C., until the reaction is complete according to HPLC-MS. After cooling to ambient temperature the reaction mixture is evaporated down, stirred with 20 ml of cold ethanol and suction filtered. The filter cake is washed with diethyl ether and dried.
Yield: 2.10 g (95% of theory)
Mass spectrum (ESI+): m/z=150 [M+H]+
57 ml of a 3 M solution of methylmagnesium bromide in diethyl ether are added to 7.00 g of 4,5-dicyano-imidazole in 80 ml of tetrahydrofuran under an argon atmosphere, while the temperature is maintained between 5° C. and 15° C.
After two hours the reaction is complete according to thin layer chromatography and the reaction mixture is diluted with 400 ml of ethyl acetate. Then 400 ml saturated ammonium chloride solution are slowly added. After ten minutes the mixture is acidified with semiconcentrated sulphuric acid and stirred for another twenty minutes before the organic phase is separated off. The aqueous phase is extracted with ethyl acetate and the combined organic phases are dried over sodium sulphate and evaporated down. The flask residue is stirred with ethyl acetate, suction filtered and washed with ethyl acetate and diethyl ether.
Yield: 3.30 g (43% of theory)
Mass spectrum (ESI+): m/z=136 [M+H]+
Prepared by reacting 2.93 g of 2-amino-1-naphthol with 3.54 g of 2-chloro-1,1,1-triethoxy-ethane in 25 ml of ethanol at 60° C.
Yield: 1.90 g (58% of theory)
Rf value: 0.55 (silica gel, petroleum ether/ethyl acetate=9:1)
Mass spectrum (ESI+): m/z=218, 220 [M+H]+
The following compounds are obtained analogously to Example XII:
Rf value: 0.90 (silica gel, methylene chloride/methanol=19:1)
Mass spectrum (ESI+): m/z=218, 220 [M+H]+
1.55 g Burgess reagent (methoxycarbonylsulphamoyl-triethylammonium-N-betaine) are added to 1.60 g of 2-bromo-7-hydroxy-3-(3-methyl-2-buten-1-yl)-3,5,6,7-tetrahydro-imidazo[4,5-c]pyridin-4-one in 20 ml methylene chloride and 4 ml of tetrahydrofuran. The reaction mixture is stirred for eight hours at 60° C., then another 0.3 equivalents Burgess reagent is added. After a further two hours the cooled reaction mixture is combined with aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate. The combined organic phases are dried over magnesium sulphate and evaporated down. The flask residue is chromatographed through a silica gel column with methylene chloride/methanol (1:0 to 10:1) as eluant.
Yield: 1.06 g (60% of theory)
Mass spectrum (ESI+): m/z=282, 284 [M+H]+
90 ml of water and 5.40 g iron powder are added to 4.15 g methyl 2-bromo-5-(1-hydroxy-2-nitro-ethyl)-3-(3-methyl-2-buten-1-yl)-3H-imidazole-4-carboxylate in 270 ml of ethanol. The mixture is refluxed, combined with 36 ml glacial acetic acid and stirred for one and a half hours at reflux temperature. The cooled reaction solution is filtered through Celite. The filtrate is evaporated down, combined with ethanol and made basic with solid potassium carbonate. The mixture is stirred for three hours at 60° C. Then the ethanol is distilled off, the flask residue is combined with water and extracted with ethyl acetate. The combined extracts are dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography over a silica gel column with methylene chloride/methanol (1:1 to 7:1) as eluant.
Yield: 1.62 g (47% of theory)
Mass spectrum (ESI+): m/z=300, 302 [M+H]+
35 ml nitromethane are added to 1.14 g caesium carbonate in 15 ml of methanol at ambient temperature. Then the mixture is combined with a solution of 3.50 g methyl 2-bromo-3-(3-methyl-2-buten-1-yl)-5-formyl-3H-imidazole-4-carboxylate in 20 ml of methanol and 5 ml methylene chloride and stirred for 15 minutes at ambient temperature. Then 0.5 ml acetic acid are added and the solution is evaporated down in vacuo. The flask residue is combined with aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate. The combined organic phases are dried over magnesium sulphate and evaporated down.
Yield: 4.15 g (99% of theory)
Mass spectrum (ESI+): m/z=362, 364 [M+H]+
40 mg sodium methoxide (95%) are added to a solution of 605 mg 2-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-cyanomethyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one in 9 ml of methanol. The mixture is stirred for one hour at ambient temperature and then neutralised with 41 μL glacial acetic acid. Then a solution of 195 mg anthranilic acid in 2 ml of methanol is added and the reaction mixture is heated to 70° C. After about two hours a white, voluminous precipitate is formed and the reaction mixture is cooled to ambient temperature. The precipitate formed is suction filtered, washed with cold methanol and dried.
Yield: 234 mg (30% of theory)
Mass spectrum (ESI+): m/z=545 [M+H]+
Preparation of the final compounds:
0.33 ml trifluoroacetic acid are added to 120 mg 2-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one in 3 ml methylene chloride while cooling with an ice bath. The reaction mixture is stirred overnight at ambient temperature.
For working up it is poured onto cooled saturated potassium carbonate solution and extracted with methylene chloride. The organic phase is separated off and evaporated down. The crude product is purified by chromatography over a silica gel column with methylene chloride/methanol (100:0 to 70:30) as eluant.
Yield: 63 mg (63% of theory)
Mass spectrum (ESI+): m/z=494 [M+H]+
The following compounds are obtained analogously to Example 1:
Mass spectrum (ESI+): m/z=478 [M+H]+
Mass spectrum (ESI+): m/z=477 [M+H]+
Rf value: 0.45 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/trifluoroacetic acid=50:50:0.1)
Mass spectrum (ESI+): m/z=492 [M+H]+
Carried out with isopropanolic hydrochloric acid (5-6 M) in methylene chloride.
Mass spectrum (ESI+): m/z=508 [M+H]+
Mass spectrum (ESI+): m/z=494 [M+H]+
Mass spectrum (ESI+): m/z=494 [M+H]+
Rf value: 0.40 (silica gel, methylene chloride/ethanol/conc. aqueous ammonia=90:10:2)
Mass spectrum (ESI+): m/z=468 [M+H]+
Mass spectrum (ESI+): m/z=468 [M+H]+
Mass spectrum (ESI+): m/z=445 [M+H]+
The following compounds may also be obtained analogously to the foregoing Examples and other methods known from the literature:
Preparation:
The active substance is mixed with calcium phosphate, corn starch, polyvinylpyrrolidone, hydroxypropylmethylcellulose and half the specified amount of magnesium stearate. Blanks 13 mm in diameter are produced in a tablet-making machine and these are then rubbed through a screen with a mesh size of 1.5 mm using a suitable machine and mixed with the rest of the magnesium stearate. This granulate is compressed in a tablet-making machine to form tablets of the desired shape.
The tablet cores thus produced are coated with a film consisting essentially of hydroxypropylmethylcellulose. The finished film-coated tablets are polished with beeswax.
Method of Preparation:
The active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the polyvinylpyrrolidone. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 50° C. it is screened again (1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed to form tablets.
Preparation:
The active substance mixed with lactose, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a screen with a mesh size of 1.5 mm. The granules, dried at 45° C., are passed through the same screen again and mixed with the specified amount of magnesium stearate. Tablets are pressed from the mixture.
Preparation:
The active substance is mixed with the excipients, passed through a screen with a mesh size of 0.75 mm and homogeneously mixed using a suitable apparatus. The finished mixture is packed into size 1 hard gelatine capsules.
Preparation:
After the suppository mass has been melted the active substance is homogeneously distributed therein and the melt is poured into chilled moulds.
Preparation:
The distilled water is heated to 70° C. The methyl and propyl p-hydroxybenzoates together with the glycerol and sodium salt of carboxymethylcellulose are dissolved therein with stirring. The solution is cooled to ambient temperature and the active substance is added and homogeneously dispersed therein with stirring. After the sugar, the sorbitol solution and the flavouring have been added and dissolved, the suspension is evacuated with stirring to eliminate air.
Preparation:
The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with common salt, filtered sterile and transferred into 2 ml ampoules.
Preparation:
The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with common salt, filtered sterile and transferred into 10 ml ampoules.
| Number | Date | Country | Kind |
|---|---|---|---|
| 103 27 439 | Jun 2003 | DE | national |
This application is a divisional of U.S. application Ser. No. 10/865,719, filed Jun. 10, 2004, now allowed, which claims benefit of U.S. Ser. No. PV 60/487,309, filed Jul. 15, 2003, and claims priority to German Application No. DE 10327439.1 filed Jun. 18, 2003, each of which is hereby incorporated by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2928833 | Leake et al. | Mar 1960 | A |
| 4005208 | Bender | Jan 1977 | A |
| 4599338 | Regnier et al. | Jul 1986 | A |
| 5041448 | Janssens | Aug 1991 | A |
| 5051517 | Findeisen | Sep 1991 | A |
| 5223499 | Greenlee | Jun 1993 | A |
| 5234897 | Findeisen et al. | Aug 1993 | A |
| 5258380 | Janssens et al. | Nov 1993 | A |
| 5266555 | Findeisen et al. | Nov 1993 | A |
| 5389642 | Dorsch et al. | Feb 1995 | A |
| 5470579 | Bonte et al. | Nov 1995 | A |
| 5719279 | Kufner-Muhl et al. | Feb 1998 | A |
| 5753635 | Buckman | May 1998 | A |
| 6303661 | Demuth | Oct 2001 | B1 |
| 6342601 | Bantick | Jan 2002 | B1 |
| 6548481 | Demuth | Apr 2003 | B1 |
| 6579868 | Asano | Jun 2003 | B1 |
| 6784195 | Hale et al. | Aug 2004 | B2 |
| 6821978 | Chackalamannil | Nov 2004 | B2 |
| 6869947 | Kanstrup | Mar 2005 | B2 |
| 7060722 | Kitajima | Jun 2006 | B2 |
| 7074794 | Kitajima | Jul 2006 | B2 |
| 7074798 | Yoshikawa | Jul 2006 | B2 |
| 7074923 | Dahanukar | Jul 2006 | B2 |
| 7109192 | Hauel et al. | Sep 2006 | B2 |
| 7192952 | Kanstrup | Mar 2007 | B2 |
| 7217711 | Eckhardt | May 2007 | B2 |
| 7235538 | Kanstrup et al. | Jun 2007 | B2 |
| 20020161001 | Kanstrup | Oct 2002 | A1 |
| 20020169174 | Chackalamannil et al. | Nov 2002 | A1 |
| 20020198205 | Himmelsbach | Dec 2002 | A1 |
| 20030105077 | Kanstrup et al. | Jun 2003 | A1 |
| 20030199528 | Kanstrup | Oct 2003 | A1 |
| 20030232987 | Dahanukar | Dec 2003 | A1 |
| 20030236272 | Carr | Dec 2003 | A1 |
| 20040034014 | Kanstrup et al. | Feb 2004 | A1 |
| 20040077645 | Himmelsbach et al. | Apr 2004 | A1 |
| 20040082570 | Yoshikawa | Apr 2004 | A1 |
| 20040087587 | Himmelsbach | May 2004 | A1 |
| 20040097510 | Himmelsbach et al. | May 2004 | A1 |
| 20040116328 | Yoshikawa et al. | Jun 2004 | A1 |
| 20040122228 | Maier | Jun 2004 | A1 |
| 20040138214 | Himmelsbach et al. | Jul 2004 | A1 |
| 20040138215 | Eckhardt | Jul 2004 | A1 |
| 20040166125 | Himmelsbach | Aug 2004 | A1 |
| 20050020574 | Hauel et al. | Jan 2005 | A1 |
| 20050026921 | Eckhardt | Feb 2005 | A1 |
| 20050130985 | Himmelsbach | Jun 2005 | A1 |
| 20050187227 | Himmelsbach et al. | Aug 2005 | A1 |
| 20050203095 | Eckhardt | Sep 2005 | A1 |
| 20050234108 | Himmelsbach et al. | Oct 2005 | A1 |
| 20050261352 | Eckhardt | Nov 2005 | A1 |
| 20060004074 | Eckhardt | Jan 2006 | A1 |
| 20060058323 | Eckhardt | Mar 2006 | A1 |
| 20060063787 | Yoshikawa | Mar 2006 | A1 |
| 20060079541 | Langkopf | Apr 2006 | A1 |
| 20060094722 | Yasuda | May 2006 | A1 |
| 20060100199 | Yoshikawa et al. | May 2006 | A1 |
| 20060142310 | Pfrengle et al. | Jun 2006 | A1 |
| 20060173056 | Kitajima et al. | Aug 2006 | A1 |
| 20060205711 | Himmelsbach et al. | Sep 2006 | A1 |
| 20060247226 | Himmelsbach et al. | Nov 2006 | A1 |
| 20070027168 | Pfrengle et al. | Feb 2007 | A1 |
| 20070088038 | Eckhardt et al. | Apr 2007 | A1 |
| 20070093659 | Bonfanti et al. | Apr 2007 | A1 |
| 20070142383 | Eckhardt et al. | Jun 2007 | A1 |
| 20070185091 | Himmelsbach et al. | Aug 2007 | A1 |
| 20070219178 | Muramoto | Sep 2007 | A1 |
| 20070281940 | Dugi et al. | Dec 2007 | A1 |
| Number | Date | Country |
|---|---|---|
| 2136288 | May 1995 | CA |
| 2418656 | Feb 2002 | CA |
| 2496325 | Mar 2004 | CA |
| 2496249 | Apr 2004 | CA |
| 2505389 | May 2004 | CA |
| 2508233 | Jun 2004 | CA |
| 2529729 | Dec 2004 | CA |
| 2543074 | Jun 2005 | CA |
| 2555050 | Sep 2005 | CA |
| 2556064 | Sep 2005 | CA |
| 2590912 | Jun 2006 | CA |
| 10109021 | Sep 2002 | DE |
| 10117803 | Oct 2002 | DE |
| 0149578 | Jul 1985 | EP |
| 0400974 | May 1990 | EP |
| 0399285 | Nov 1990 | EP |
| 0412358 | Feb 1991 | EP |
| 0524482 | Jan 1993 | EP |
| 0657454 | Jun 1995 | EP |
| 1054012 | Nov 2000 | EP |
| 1338595 | Aug 2003 | EP |
| 1514552 | Mar 2005 | EP |
| 1537880 | Aug 2005 | EP |
| 385302 | Apr 1973 | ES |
| 2707641 | Jan 1995 | FR |
| S37-4895 | Jun 1962 | JP |
| 2003300977 | Oct 2003 | JP |
| 2006045156 | Feb 2006 | JP |
| 9107945 | Jun 1991 | WO |
| 9403456 | Feb 1994 | WO |
| 9929695 | Jun 1999 | WO |
| 0202560 | Jan 2002 | WO |
| 0214271 | Feb 2002 | WO |
| 0224698 | Mar 2002 | WO |
| 02068420 | Sep 2002 | WO |
| 03004496 | Jan 2003 | WO |
| 03024965 | Mar 2003 | WO |
| 03057200 | Jul 2003 | WO |
| 03104229 | Dec 2003 | WO |
| 2004018467 | Mar 2004 | WO |
| 2004018468 | Mar 2004 | WO |
| 2004028524 | Apr 2004 | WO |
| 2004033455 | Apr 2004 | WO |
| 2004041820 | May 2004 | WO |
| 2004046148 | Jun 2004 | WO |
| 2004048379 | Jun 2004 | WO |
| 2004050658 | Jun 2004 | WO |
| 2004096806 | Nov 2004 | WO |
| 2004108730 | Dec 2004 | WO |
| 2004111051 | Dec 2004 | WO |
| 2005058901 | Jun 2005 | WO |
| 2005082906 | Sep 2005 | WO |
| 2005085246 | Sep 2005 | WO |
| 2006029769 | Mar 2006 | WO |
| 2006048427 | May 2006 | WO |
| 2006068163 | Jun 2006 | WO |
| 2007017423 | Feb 2007 | WO |
| 2008017670 | Feb 2008 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20090258856 A1 | Oct 2009 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60487309 | Jul 2003 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10865719 | Jun 2004 | US |
| Child | 12489716 | US |
